Cargando…

A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors

Bladder cancer (BC) is a leading cause of male cancer-related deaths globally. Immunotherapy is showing promise as a treatment option for BC. Numerous studies suggested that necroptosis and long noncoding RNAs (lncRNAs) were critical players in the development of cancers and interacting with cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Han, Lv, Zhengtong, Liu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578762/
https://www.ncbi.nlm.nih.gov/pubmed/37832111
http://dx.doi.org/10.1097/MD.0000000000035196
_version_ 1785121579519180800
author Li, Han
Lv, Zhengtong
Liu, Ming
author_facet Li, Han
Lv, Zhengtong
Liu, Ming
author_sort Li, Han
collection PubMed
description Bladder cancer (BC) is a leading cause of male cancer-related deaths globally. Immunotherapy is showing promise as a treatment option for BC. Numerous studies suggested that necroptosis and long noncoding RNAs (lncRNAs) were critical players in the development of cancers and interacting with cancer immunity. However, the prognostic value of necroptosis-related lncRNAs and their impact on immunotherapeutic response in patients with BC have yet to be well examined. Thus, this study aims to find new biomarkers for predicting prognosis and determining immune subtypes of BC to select appropriate patients from a heterogeneous population. The clinicopathology and transcriptome information from The Cancer Genome Atlas (TCGA) was downloaded, and coexpression analysis was performed to identify necroptosis-related lncRNAs. Then LASSO regression was employed to construct a prediction signature. The signature performance was evaluated by Kaplan–Meier (K–M) method, Time-dependent receiver operating characteristics (ROC). The functional enrichment, immune infiltration, immune checkpoint activation, and the half-maximal inhibitory concentration (IC50) of common drugs in risk groups were compared. The consensus clustering analysis based on lncRNAs associated with necroptosis was made to get 2 clusters to identify hot and cold tumors further. Lastly, the immune response between cold and hot tumors was discussed. In this study, a model containing 5 necroptosis-related lncRNAs was constructed. The risk score distribution of these lncRNAs was compared between low- and high-risk groups in the training, testing, and entire sets. K–M analysis showed that the low-risk patients had significantly better prognosis. The area under the ROC curve (AUC) for the 1-, 3-, and 5-year ROC curves in the entire sets were 0.690, 0.709, and 0.722, respectively. High-risk patients were enriched in lncRNAs related to tumor immunity and had better immune cell infiltration and immune checkpoint activation. Hot tumors and cold tumors were effectively distinguished by clusters 1 and cluster 2, respectively. We developed a necroptosis-related signature based on 5 prognostic lncRNAs, expected to become a new tool for evaluating the prognosis of patients with BC and classifying hot or cold tumors, thus facilitating the development of precision therapy for BC.
format Online
Article
Text
id pubmed-10578762
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105787622023-10-17 A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors Li, Han Lv, Zhengtong Liu, Ming Medicine (Baltimore) 7300 Bladder cancer (BC) is a leading cause of male cancer-related deaths globally. Immunotherapy is showing promise as a treatment option for BC. Numerous studies suggested that necroptosis and long noncoding RNAs (lncRNAs) were critical players in the development of cancers and interacting with cancer immunity. However, the prognostic value of necroptosis-related lncRNAs and their impact on immunotherapeutic response in patients with BC have yet to be well examined. Thus, this study aims to find new biomarkers for predicting prognosis and determining immune subtypes of BC to select appropriate patients from a heterogeneous population. The clinicopathology and transcriptome information from The Cancer Genome Atlas (TCGA) was downloaded, and coexpression analysis was performed to identify necroptosis-related lncRNAs. Then LASSO regression was employed to construct a prediction signature. The signature performance was evaluated by Kaplan–Meier (K–M) method, Time-dependent receiver operating characteristics (ROC). The functional enrichment, immune infiltration, immune checkpoint activation, and the half-maximal inhibitory concentration (IC50) of common drugs in risk groups were compared. The consensus clustering analysis based on lncRNAs associated with necroptosis was made to get 2 clusters to identify hot and cold tumors further. Lastly, the immune response between cold and hot tumors was discussed. In this study, a model containing 5 necroptosis-related lncRNAs was constructed. The risk score distribution of these lncRNAs was compared between low- and high-risk groups in the training, testing, and entire sets. K–M analysis showed that the low-risk patients had significantly better prognosis. The area under the ROC curve (AUC) for the 1-, 3-, and 5-year ROC curves in the entire sets were 0.690, 0.709, and 0.722, respectively. High-risk patients were enriched in lncRNAs related to tumor immunity and had better immune cell infiltration and immune checkpoint activation. Hot tumors and cold tumors were effectively distinguished by clusters 1 and cluster 2, respectively. We developed a necroptosis-related signature based on 5 prognostic lncRNAs, expected to become a new tool for evaluating the prognosis of patients with BC and classifying hot or cold tumors, thus facilitating the development of precision therapy for BC. Lippincott Williams & Wilkins 2023-10-13 /pmc/articles/PMC10578762/ /pubmed/37832111 http://dx.doi.org/10.1097/MD.0000000000035196 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 7300
Li, Han
Lv, Zhengtong
Liu, Ming
A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors
title A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors
title_full A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors
title_fullStr A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors
title_full_unstemmed A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors
title_short A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors
title_sort five necroptosis-related lncrna signature predicts the prognosis of bladder cancer and identifies hot or cold tumors
topic 7300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578762/
https://www.ncbi.nlm.nih.gov/pubmed/37832111
http://dx.doi.org/10.1097/MD.0000000000035196
work_keys_str_mv AT lihan afivenecroptosisrelatedlncrnasignaturepredictstheprognosisofbladdercancerandidentifieshotorcoldtumors
AT lvzhengtong afivenecroptosisrelatedlncrnasignaturepredictstheprognosisofbladdercancerandidentifieshotorcoldtumors
AT liuming afivenecroptosisrelatedlncrnasignaturepredictstheprognosisofbladdercancerandidentifieshotorcoldtumors
AT lihan fivenecroptosisrelatedlncrnasignaturepredictstheprognosisofbladdercancerandidentifieshotorcoldtumors
AT lvzhengtong fivenecroptosisrelatedlncrnasignaturepredictstheprognosisofbladdercancerandidentifieshotorcoldtumors
AT liuming fivenecroptosisrelatedlncrnasignaturepredictstheprognosisofbladdercancerandidentifieshotorcoldtumors